Sugi Predict

Sugi Predict / Compounds / SCHEMBL1983142

SCHEMBL1983142

SCHEMBL1983142

CC(C)(C)NC(=O)C1CCCN1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ PRCP P42785 3/20 0.49
▸ DPP7 Q9UHL4 2/20 0.43
▸ HTR2C P28335 2/20 0.40
▸ NOS2 P35228 2/20 0.39
▸ NOS3 P29474 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ DPP4 P27487 3/20 0.39
▸ FAP Q12884 1/20 0.39
▸ DPP8 Q6V1X1 1/20 0.39
▸ DPP9 Q86TI2 1/20 0.39
▸ TLR2 O60603 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ CTSC P53634 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17676963 1.00 L3MBTL1 (0.54) L3MBTL1PRCPDPP7HTR2CNOS2
SCHEMBL495672 1.00 L3MBTL1 (0.54) L3MBTL1PRCPDPP7HTR2CNOS2
Hydrochloric Acid SCHEMBL6860843 0.98 L3MBTL1 (0.53) L3MBTL1PRCPDPP7HTR2CNOS2
SCHEMBL7268303 0.94 L3MBTL1 (0.57) L3MBTL1PRCPDPP7HTR2CHTR2B
SCHEMBL4901407 0.94 L3MBTL1 (0.57) L3MBTL1PRCPDPP7HTR2CHTR2B
SCHEMBL26501818 0.90 L3MBTL1 (0.54) L3MBTL1PRCPDPP7NOS2NOS3
SCHEMBL15373851 0.90 L3MBTL1 (0.54) L3MBTL1PRCPDPP7NOS2NOS3
SCHEMBL27284993 0.84 PRCP (0.45) L3MBTL1PRCPDPP7HTR2CNOS2
SCHEMBL7385460 0.82 PRCP (0.48) L3MBTL1PRCPDPP7HTR2CHTR2B
SCHEMBL7385456 0.82 PRCP (0.48) L3MBTL1PRCPDPP7HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130046077-A1 DOLASTATIN 15 DERIVATIVES ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2013-02-21 — — US claimed
US-8163698-B2 Dolastatin 15 derivatives ABBOTT GMBH & CO. KG (DE) 2012-04-24 — — US claimed
US-20100099843-A1 DOLASTATIN 15 DERIVATIVES ABBOTT GMBH & CO. KG (DE) 2010-04-22 — — US claimed
US-20250346574-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-13 — — US disclosed
EP-4320125-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2024-02-14 — — EP disclosed
CN-117396477-A Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer 百时美施贵宝公司 2024-01-12 — — CN disclosed
US-20230131535-A1 ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-04-27 — — US disclosed
WO-2022216573-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2022-10-13 — — WO disclosed
US-10005740-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-06-26 — — US disclosed
US-20180118696-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-05-03 — — US disclosed
US-9783507-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-10-10 — — US disclosed
EP-1463733-A4 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2006-01-11 — — EP disclosed
EP-0991658-B1 DOLASTATIN 15 DERIVATIVES ABBOTT GMBH & CO KG (DE) 2005-12-28 — — EP disclosed
EP-1463733-A2 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2004-10-06 — — EP disclosed
WO-2003050064-A2 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2003-06-19 — — WO disclosed
US-6458765-B1 POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION BASF AKTIENGESELLSCHAFT (DE) 2002-10-01 — — US disclosed
US-6143721-A FOR TREATING CANCER IN MAMMALS BASF AKTIENGESELLSCHAFT (DE) 2000-11-07 — — US disclosed
EP-0991658-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-04-12 — — EP disclosed
WO-1999003879-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1999-01-28 — — WO disclosed
CN-1064683-A New beta-amino-alpha-hydroxycarboxylic acids and uses thereof SANKYO CO (JP) 1992-09-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099843-A1 DOLASTATIN 15 DERIVATIVES DDOST, DBI, DAO L3MBTL1 1315/4885PRCP 2846/4885DPP7 2431/4885
US-20250346574-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER RECQL, H1-5, H1-3 L3MBTL1 1769/4885PRCP 1364/4885DPP7 2993/4885
US-10005740-B2 Neprilysin inhibitors MME, REN, AGTR1 L3MBTL1 2162/4885PRCP 37/4885DPP7 50/4885
US-20230131535-A1 ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNK3 L3MBTL1 3877/4885PRCP 4099/4885DPP7 1373/4885
US-20180118696-A1 NEPRILYSIN INHIBITORS MME, REN, AGTR1 L3MBTL1 2162/4885PRCP 37/4885DPP7 50/4885
US-20130046077-A1 DOLASTATIN 15 DERIVATIVES DDOST, DBI, DAO L3MBTL1 1315/4885PRCP 2846/4885DPP7 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.